Arguments in favor of remdesivir for treating SARS-CoV-2 infections

Very cool article summarizing potential of remdesivir as potential therapeutic vs Covid19. Submitted 16-Feb-2020, published 6-Mar-2020, and as of today 15-Mar-2020, it is the third-most-recently published article about remdesivir vs covid19 as indexed by google scholar [1].

interesting notes: remdesivir was given to the first reported covid19 patient in the usa under a compassionate use exception. Impossible to say if it helped, but the patient's condition did improve the next day.

> "Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) was initiated on the evening of day 7 (illness day 11), and no adverse events were observed in association with the infusion." [2]

Also see "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)" [3]

[1] https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=remdes...

[2] https://www.nejm.org/doi/10.1056/NEJMoa2001191

[3] https://www.nature.com/articles/d41573-020-00016-0

It should be noted that Remdesivir is already being actively given to patients in critical/severe state in several EU countries.

This is outside clinical trials.

See a compilation of updated guidelines I submitted yesterday.

These are the guidelines for Belgium, France, Italy, Switzerland and the Netherlands.

https://news.ycombinator.com/item?id=22574183

Or for direct link

https://web.archive.org/web/20200314093143/https://epidemio....

France is clearly pushing Remdesivir while others seem to consider it mainly for severe to critical cases. Surprisingly France is also somewhat dropping the cheap chloroquine option in favor of Remdesivir and Lopinavir/ritonavir.